Sidney Smith, MD
MOHS-Micrographic Surgery · Savannah, GANPI 1104817410
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,986 of the $9,181 with a category attached, or 87.0%. It is spread thinly across 32 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations.
Across 399 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$1K
- Pfizer$1K
- Convatec Inc.$952
- Regeneron Healthcare Solutions, Inc.$935
- AbbVie$895
- Sanofi$693
- plus $4K from 26 others
Across 226 payments — averaging $3838.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$259K
- Sun Pharmaceutical Industries Inc.$223K
- UCB SA$165K
- Amgen$84K
- Sanofi US Services Inc.$62K
- Pfizer$53K
- plus $22K from 3 others
What the payments were for
- Travel & lodging$5796%
- Food & beverage$7,98687%
- Education$6167%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 52 | $1,104 |
| Pfizer | 66 | $1,054 |
| Convatec Inc. | 6 | $952 |
| Regeneron Healthcare Solutions, Inc. | 34 | $935 |
| AbbVie | 54 | $895 |
| Sanofi | 27 | $693 |
| Incyte Corporation | 19 | $555 |
| Amgen | 27 | $502 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 17 | $398 |
| UCB, Inc. | 8 | $306 |
| Johnson & Johnson | 7 | $298 |
| Novartis | 16 | $277 |
| E.r. Squibb & Sons, L.L.C. | 15 | $237 |
| LEO Pharma Inc. | 12 | $224 |
| Genentech USA, Inc. | 5 | $109 |
| Lilly USA, LLC | 6 | $107 |
| Organogenesis Inc. | 3 | $64 |
| Galderma Laboratories, L.p. | 2 | $59 |
| Stemline Therapeutics Inc. | 1 | $57 |
| Dermavant Sciences, Inc. | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Bristol Myers Squibb | 3 | $50 |
| Almirall LLC | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Organon | 2 | $23 |
| Aclaris Therapeutics, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Boston Scientific | 1 | $14 |
| DUSA Pharmaceuticals, Inc. | 1 | $13 |
| Mayne Pharma Commercial LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,181 in reported general payments places this provider in the 80th percentile of 40 mohs-micrographic surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 71 | $282,775 |
| Humira(Cf) PenAdalimumab | 13 | $177,104 |
| RinvoqUpadacitinib | 14 | $85,793 |
| OtezlaApremilast | 13 | $63,140 |
| Dupixent SyringeDupilumab | 12 | $52,913 |
| Fluorouracil | 126 | $7,791 |
| Clobetasol Propionate | 151 | $5,608 |
| Triamcinolone Acetonide | 182 | $3,022 |
| Clindamycin Phosphate | 55 | $2,467 |
| Pimozide | 11 | $2,096 |
| Tacrolimus | 26 | $1,990 |
| Halobetasol Propionate | 13 | $1,394 |
| Desonide | 13 | $1,275 |
| Metronidazole | 14 | $1,199 |
| Ketoconazole | 81 | $1,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $895 | $85,79314 claims |
| AmgenOtezla | $502 | $63,14013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 40 mohs-micrographic surgery providers in Georgia.
Other mohs-micrographic surgery in Savannah
- Wallace NozileStockbridge$213K
- Brandon BurrowayDuluth$30K
- John KayalMarietta$27K
- David HarveyNewnan$17K
- David OlanskyAtlanta$13K
- David KentMacon$11K
- Diamondis PapadopoulosAtlanta$9K
- Steven KentMacon$8K
- Danielle LazzaraMilton$7K
- Jane UnaezeAthens$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.